Research note by Capital Networks following the milestone immunogenicity data which keeps Avacta on track for first therapeutic Affimer into the clinic.
See also, Avacta's presentation: Immunogenicity Data: A Key Milestone
Analysis and commentary by Dr Riccardo Lowi who originally trained as a doctor and chose to apply his knowledge in the commercial setting as a healthcare equity analyst.
See the latest note about Avacta from Hardman & Co
See the latest note from Hardman & Co about Avacta.